Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    GR40550
Previous Study | Return to List | Next Study

This Study Will Evaluate the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Participants With Diabetic Macular Edema Compared With Intravitreal Ranibizumab (Pagoda)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04108156
Recruitment Status : Active, not recruiting
First Posted : September 30, 2019
Last Update Posted : September 16, 2021
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche

Tracking Information
First Submitted Date  ICMJE September 26, 2019
First Posted Date  ICMJE September 30, 2019
Last Update Posted Date September 16, 2021
Actual Study Start Date  ICMJE September 30, 2019
Estimated Primary Completion Date October 25, 2022   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: December 15, 2020)
Change in BCVA score from baseline averaged over Weeks 60 and 64 as measured using the ETDRS chart in the efficacy population [ Time Frame: Baseline to Week 64 ]
BCVA = Best-Corrected Visual Acuity ETDRS = Early Treatment Diabetic Retinopathy Study A vision score of 20/20 vision is considered normal. A score of 20/200 is considered being legally blind.
Original Primary Outcome Measures  ICMJE
 (submitted: September 26, 2019)
Change in BCVA score from baseline averaged over Weeks 48 and 52 as measured using the ETDRS chart [ Time Frame: Baseline to Week 52 ]
BCVA = Best-Corrected Visual Acuity ETDRS = Early Treatment Diabetic Retinopathy Study A vision score of 20/20 vision is considered normal. A score of 20/200 is considered being legally blind.
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: December 15, 2020)
  • Change in BCVA score from baseline averaged over Weeks 60 and 64 as measured with use of the ETDRS chart in the per protocol population [ Time Frame: Baseline to Week 64 ]
    ETDRS-DRSS = ETDRS Diabetic Retinopathy Severity Scale
  • Percentage of participants with a ≥2-step improvement from baseline on the ETDRS-DRSS at Week 64 in the efficacy population [ Time Frame: Baseline to Week 64 ]
  • Percentage of participants with a ≥2-step improvement from baseline on the ETDRS-DRSS at Week 64 in the per protocol population [ Time Frame: Baseline to Week 64 ]
  • Change from baseline in BCVA as measured on the ETDRS chart over time [ Time Frame: Baseline up to Week 120 ]
  • Percentage of participants who lose <10, and <5 letters in BCVA from baseline over time [ Time Frame: Baseline up to Week 120 ]
  • Percentage of participants who gain ≥15, ≥10, ≥5, ≥0 letters in BCVA from baseline over time [ Time Frame: Baseline up to Week 120 ]
  • Percentage of participants with a BCVA Snellen equivalent of 20/40 or better over time [ Time Frame: Baseline up to Week 120 ]
  • Percentage of participants with a BCVA Snellen equivalent of 20/200 or worse over time [ Time Frame: Baseline up to Week 120 ]
  • Percentage of participants with a ≥3-step improvement from baseline on the ETDRS-DRSS at Week 64 [ Time Frame: Baseline to Week 64 ]
  • Percentage of participants with a ≥2-step improvement from baseline on the ETDRS-DRSS over time [ Time Frame: Baseline up to Week 120 ]
  • Percentage of participants with a ≥3-step improvement from baseline on the ETDRS-DRSS over time [ Time Frame: Baseline up to Week 120 ]
  • Time to ≥2-step worsening from baseline on the ETDRS-DRSS [ Time Frame: Baseline up to Week 120 ]
  • Time to ≥3-step worsening from baseline on the ETDRS-DRSS [ Time Frame: Baseline up to Week 120 ]
  • Change from baseline in ETDRS-DRSS score over time [ Time Frame: Baseline up to Week 120 ]
  • Change from baseline in CST as measured on SD-OCT at Week 64 [ Time Frame: Baseline to Week 64 ]
    CST = central subfield thickness SD-OCT = spectral domain optical coherence tomography
  • Change from baseline in CST as measured on SD-OCT over time [ Time Frame: Baseline up to Week 120 ]
  • Change from baseline in total macular volume as measured on SD-OCT over time [ Time Frame: Baseline up to Week 120 ]
  • Percentage of participants with DME (defined as CST ≥325 μm on SD-OCT) over time [ Time Frame: Baseline up to Week 120 ]
    DME = diabetic macular edema
  • Time to PDR (defined as a score ≥60 on the ETDRS-DRSS) [ Time Frame: Baseline up to Week 120 ]
    PDR = proliferative diabetic retinopathy
  • Percentage of participants who do not undergo supplemental treatment with intravitreal ranibizumab within each refill-exchange interval [ Time Frame: Baseline up to Week 120 ]
  • Percentage of participants who report preferring PDS treatment compared with intravitreal ranibizumab treatment, as measured by the PDS Patient Preference Questionnaire (PPPQ) at Week 64 among participants in the PDS arm efficacy population [ Time Frame: Baseline to Week 64 ]
  • Percentage of participants who report preferring PDS treatment compared with intravitreal ranibizumab treatment, as measured by the PDS Patient Preference Questionnaire (PPPQ) at Week 64 among participants in per protocol population [ Time Frame: Baseline to Week 64 ]
  • Percentage of participants who report preferring PDS treatment compared with intravitreal ranibizumab treatment, as measured by the PDS Patient Preference Questionnaire (PPPQ) at Week 64 [ Time Frame: Baseline to Week 64 ]
    Participants in in a subset of patients with bilateral disease who are simultaneously receiving ranibizumab via study eye PDS implant and fellow eye intravitreal injection
  • Incidence and severity of ocular adverse events [ Time Frame: Baseline to Week 120 ]
  • Incidence and severity of non-ocular adverse events [ Time Frame: Baseline up to Week 120 ]
  • Incidence, severity, and duration of adverse events of special interest [ Time Frame: Baseline up to Week 120 ]
  • Incidence, severity, and duration of PDS-associated adverse events of special interest during the postoperative period (up to 37 days after initial implantation) and follow-up period (>37 days after implantation surgery) [ Time Frame: Baseline up to Week 120 ]
  • Serum concentration of ranibizumab observed over time [ Time Frame: Baseline up to Week 120 ]
  • PK parameter value area under the concentration- time curve over 24 weeks (AUC24W) [ Time Frame: Baseline to Week 24 ]
  • Pharmacokinetic (PK) parameter maximum serum concentration (Cmax) [ Time Frame: Baseline up to Week 120 ]
  • PK Parameter minimum serum concentration (Cmin) [ Time Frame: Baseline up to Week 120 ]
  • PK parameter half-life (t1/2) after PDS implant insertion [ Time Frame: Baseline up to Week 120 ]
  • Prevalence of anti-drug antibodies (ADAs) at baseline and incidence of ADAs during the study [ Time Frame: Baseline up to Week 120 ]
Original Secondary Outcome Measures  ICMJE
 (submitted: September 26, 2019)
  • Percentage of participants with a ≥2-step improvement from baseline on the ETDRS-DRSS at Week 52 [ Time Frame: Baseline to Week 52 ]
    ETDRS-DRSS = ETDRS Diabetic Retinopathy Severity Scale
  • Change from baseline in BCVA as measured on the ETDRS chart over time [ Time Frame: Baseline up to Week 120 ]
  • Percentage of participants who lose <15, <10, and <5 letters in BCVA from baseline over time [ Time Frame: Baseline up to Week 120 ]
  • Percentage of participants who gain ≥15, ≥10, ≥5, ≥0 letters in BCVA from baseline over time [ Time Frame: Baseline up to Week 120 ]
  • Percentage of participants with a BCVA Snellen equivalent of 20/40 or better over time [ Time Frame: Baseline up to Week 120 ]
  • Percentage of participants with a BCVA Snellen equivalent of 20/200 or worse over time [ Time Frame: Baseline up to Week 120 ]
  • Percentage of participants with a ≥3-step improvement from baseline on the ETDRS-DRSS at Week 52 [ Time Frame: Baseline to Week 52 ]
  • Percentage of participants with a ≥2-step improvement from baseline on the ETDRS-DRSS over time [ Time Frame: Baseline up to Week 120 ]
  • Percentage of participants with a ≥3-step improvement from baseline on the ETDRS-DRSS over time [ Time Frame: Baseline up to Week 120 ]
  • Percentage of participants with a ≥2-step worsening from baseline on the ETDRS-DRSS over time [ Time Frame: Baseline up to Week 120 ]
  • Percentage of participants with a ≥3-step worsening from baseline on the ETDRS-DRSS over time [ Time Frame: Baseline up to Week 120 ]
  • Change from baseline in ETDRS-DRSS score over time [ Time Frame: Baseline up to Week 120 ]
  • Change from baseline in CST as measured on SD-OCT at Week 52 [ Time Frame: Baseline to Week 52 ]
    CST = central subfield thickness SD-OCT = spectral domain optical coherence tomography
  • Change from baseline in CST as measured on SD-OCT over time [ Time Frame: Baseline up to Week 120 ]
  • Change from baseline in total macular volume as measured on SD-OCT over time [ Time Frame: Baseline up to Week 120 ]
  • Percentage of participants with DME (defined as CST ≥325 μm on SD-OCT) over time [ Time Frame: Baseline up to Week 120 ]
    DME = diabetic macular edema
  • Percentage of participants with PDR (defined as a score ≥60 on the ETDRS-DRSS) over time [ Time Frame: Baseline up to Week 120 ]
    PDR = proliferative diabetic retinopathy
  • Incidence and severity of ocular adverse events [ Time Frame: Baseline to Week 120 ]
  • Incidence and severity of non-ocular adverse events [ Time Frame: Baseline up to Week 120 ]
  • Incidence, severity, and duration of adverse events of special interest [ Time Frame: Baseline up to Week 120 ]
  • Incidence, severity, and duration of PDS-associated adverse events of special interest during the postoperative period (up to 37 days after initial implantation) and follow-up period (>37 days after implantation surgery) [ Time Frame: Baseline up to Week 120 ]
  • Serum concentration of ranibizumab observed over time [ Time Frame: Baseline up to Week 120 ]
  • PK parameter value area under the concentration- time curve over 24 weeks (AUC24W) [ Time Frame: Baseline to Week 24 ]
  • Pharmacokinetic (PK) parameter maximum serum concentration (Cmax) [ Time Frame: Baseline up to Week 120 ]
  • PK Parameter minimum serum concentration (Cmin) [ Time Frame: Baseline up to Week 120 ]
  • PK parameter half-life (t1/2) after PDS implant insertion [ Time Frame: Baseline up to Week 120 ]
  • Prevalence of anti-drug antibodies (ADAs) at baseline and incidence of ADAs during the study [ Time Frame: Baseline up to Week 120 ]
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE This Study Will Evaluate the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Participants With Diabetic Macular Edema Compared With Intravitreal Ranibizumab
Official Title  ICMJE A Phase III, Multicenter, Randomized, Visual Assessor-Masked, Active-comparator Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Patients With Diabetic Macular Edema (Pagoda)
Brief Summary This study will evaluate the efficacy, safety, and pharmacokinetics of the Port Delivery System with Ranibizumab (PDS) in Participants with Diabetic Macular Edema (DME) when treated every 24 weeks (Q24W) compared with intravitreal ranibizumab 0.5 mg every 4 weeks (Q4W).
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Diabetic Macular Edema
Intervention  ICMJE
  • Drug: PDS Implant Pre-Filled with 100 mg/mL Ranibizumab
    Will be administered as per the schedule described in individual arm.
  • Drug: Intravitreal Ranibizumab 0.5 mg Injection
    Will be administered as per the schedule described in individual arm.
Study Arms  ICMJE
  • Experimental: PDS Arm
    Participants randomized to the PDS arm will receive intravitreal ranibizumab injection every 4 weeks (loading phase) and will then have the PDS implant (pre-filled with ranibizumab) surgically inserted. PDS implant refill-exchange procedures will be performed on a fixed interval every 24-weeks (Q24W) thereafter
    Intervention: Drug: PDS Implant Pre-Filled with 100 mg/mL Ranibizumab
  • Active Comparator: Intravitreal Arm
    Participants randomized to the intravitreal arm will receive intravitreal ranibizumab injection every 4 weeks until they receive the PDS implant (pre-filled with ranibizumab). PDS implant refill-exchange procedures will be performed on a fixed interval Q24W thereafter.
    Intervention: Drug: Intravitreal Ranibizumab 0.5 mg Injection
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Estimated Enrollment  ICMJE
 (submitted: September 26, 2019)
545
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE September 10, 2024
Estimated Primary Completion Date October 25, 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Age ≥18 years at time of signing Informed Consent Form
  • Documented diagnosis of diabetes mellitus (Type 1 or Type 2)
  • HbA1c level of ≤10% within 2 months prior to screening or at screening

Study eye

  • Macular thickening secondary to DME involving the center of the fovea with CST ≥325 um on SD-OCT at screening
  • BCVA score of 78 to 25 letters (20/32 to 20/320 approximate Snellen equivalent)

Exclusion Criteria:

  • High-risk proliferative diabetic retinopathy
  • Active intraocular inflammation (grade trace or above)
  • Suspected or active ocular or periocular infection of either eye
  • Uncontrolled ocular hypertension or glaucoma and any such condition the investigator determines may require a glaucoma-filtering surgery during a patient's participation in the study
  • Cerebrovascular accident or myocardial infarction within 6 months prior to randomization
  • Atrial fibrillation diagnosis or worsening within 6 months prior to randomization
  • Uncontrolled blood pressure
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04108156
Other Study ID Numbers  ICMJE GR40550
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: Yes
Plan Description: Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.clinicalstudydatarequest.com). Further details on Roche's criteria for eligible studies are available here (https://clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-Roche.aspx). For further details on Roche's Global Policy on Sharing of Clinical Study Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
Responsible Party Hoffmann-La Roche
Study Sponsor  ICMJE Hoffmann-La Roche
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Clinical Trials Hoffmann-La Roche
PRS Account Hoffmann-La Roche
Verification Date September 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP